Deepa Prasad - 10 Jun 2025 Form 4 Insider Report for Design Therapeutics, Inc. (DSGN)

Reporting relationship: Director
Issuer ticker: DSGN
Reported as of: 10 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2025, 16:30:24 UTC
Prior SEC filing: 19 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Mustapha Parekh, Attorney-in-Fact

Key filing fact

Deepa Prasad filed Form 4 for Design Therapeutics, Inc. (DSGN) on 12 Jun 2025.

Key facts

This page summarizes Deepa Prasad's Form 4 filing for Design Therapeutics, Inc. (DSGN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2025, 16:30.

Change

Previous filing in this sequence was filed on 19 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001867165 Primary reporting owner

Prasad Deepa

Relationship: Director
Address: C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD
Signature: /s/ Mustapha Parekh, Attorney-in-Fact
Signature date: 12 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DSGN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +19,000
Change %
Price: $0.000000
Shares after: 19,000
Date: 10 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,000
Exercise price: $4.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option vest in equal monthly installments over 12 months following June 10, 2025 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.